4 treatment settings, 3 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Lumpectomy to 2 mm margins followed by whole-breast radiotherapy (hypofractionated), with radiotherapy omission considered for low-risk lesions (RTOG 9804 criteria or genomic assay).
IMRT and IGRT shape the radiation beam to the tumour's outline from multiple angles and check the patient's position with a scan before every session, so surrounding organs receive less dose. Fewer, larger doses are now standard in breast and prostate cancer, but a low-dose bath still spreads across normal tissue.
A 21-gene test that tells most women with early hormone-positive breast cancer whether they can safely skip chemotherapy.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.
Mastectomy with sentinel node biopsy and optional reconstruction; radiotherapy not needed after mastectomy with clear margins.
Sentinel lymph node biopsy identifies and samples the first draining node or nodes to assess spread. The sampled result does not describe every node or prove whole-body absence.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.
Tamoxifen (or anastrozole in postmenopausal women) for five years to reduce ipsilateral and contralateral breast events; low-dose tamoxifen is an option (TAM-01).
The original targeted cancer drug (1977): a pill that blocks oestrogen's effect on breast cancer and halves recurrence, still essential for premenopausal women.
Pills that block or remove oestrogen signalling, the mainstay of treatment for hormone-driven breast cancer for 50 years.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hot flushes · ATAC, tamoxifen arm, US label (36% with anastrozole) | 41% | - |
| Cataract · ATAC, tamoxifen arm, US label (6% with anastrozole) | 7% | - |
| Venous thromboembolism · ATAC, tamoxifen arm, US label (3% with anastrozole) | 5% | - |
| Endometrial cancer · ATAC, tamoxifen arm, women with an intact uterus, US label (0.2% with anastrozole); NSABP P-1 found 33 versus 14 invasive endometrial cancers with tamoxifen versus placebo | 0.6% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Active monitoring with mammography every six months and optional endocrine therapy, in trials (COMET, LORIS, LORD) or after shared decision-making where guidelines allow.
For low-risk prostate cancer, monitoring with PSA, MRI, and repeat biopsy instead of treating, because most such cancers never cause harm.
Mammography uses low-dose X-rays to show breast patterns such as masses and calcifications. Tomosynthesis reconstructs images from several angles; its sections are computed images, not tissue slides.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.